PO.CL05.02 · 临床研究

通过亲和力调谐的结合体和模块化架构优化对 PTPRZ1 CAR T 细胞进行多尺度工程化

Multiscale engineering of PTPRZ1 CAR T cells through affinity-tuned binders and modular architecture optimization

编号 5191 展板 9 时间 4/21 09:00–12:00 区域 Section 40 主讲 Aditya Mohan, BS
分会场 Adoptive Cell Therapy 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Aditya A. Mohan1, Barbara Lipes1, Rushil Yerrabelli1, Kisha Kamini Patel2, Charla Gentry1, Ariel Gonzalez1, John Sampson3, Peter E. Fecci4, Michael Gunn1, Anoop Patel1

1Duke University, Durham, NC,2University of Pennsylvania, Philadelphia, PA,3University of Colorado, Aurora, CO,4Duke University Medical Center, Durham, NC

摘要 Abstract

中文摘要
胶质母细胞瘤仍普遍致命,其复发迅速,中位生存期不足两年。目前胶质母细胞瘤中的 CAR T 方法受限于缺乏均匀表达且具有治疗可操作性的抗原。利用整合的单细胞和单核图谱,我们鉴定出 PTPRZ1 是在各种恶性胶质母细胞瘤状态中持续且高表达的表面抗原,而在非肿瘤性神经谱系中表达极少。为转化这一靶点,我们开发了一条结合小鼠免疫、针对 PTPRG 反向筛选的噬菌体展示以及基于酵母的定向进化的结合体工程化流程,生成了一组识别相同 PTPRZ1 表位、具有一系列亲和力的 scFv 和纳米抗体结合体。该组合体能够系统地调谐 CAR 抗原敏感性和功能阈值,并可直接比较结合体格式和亲和力如何塑造 CAR 对内源性抗原的活性。我们将这些亲和力梯度结合体整合到模块化 CAR 骨架中,构建了一个改变铰链结构域、跨膜区和共刺激模块的组合 CAR 文库。将转导了混合 CAR 文库的原代人 T 细胞针对患者来源的胶质瘤干细胞进行筛选,以定量每个架构模块作为独立组分如何影响 CAR 功能,以及模块组合如何协同增强活化、细胞毒性、增殖、抗耗竭能力以及在慢性刺激下的持久性。这一筛选策略还使得能够鉴定出在实体瘤环境中支持持久性和代谢健适度的反复出现的架构特征。个体验证研究证实,靶向相同表位的 scFv 和纳米抗体 CAR 均表现出不同的活化和持久性特征,且最佳性能源于铰链、跨膜和共刺激结构域的特定配对。使用人癫痫来源皮层切片培养物进行的安全性研究显示,暴露于 PTPRZ1 靶向 CAR T 细胞后,脱靶细胞毒性极小且神经结构得以保留。总之,这些数据提名亲和力调谐的 PTPRZ1 结合体和优化的 CAR 架构为强有力的转化候选物,并为改善实体瘤中的 CAR T 疗法提供了可推广的设计原则。
查看英文原文 English abstract
Glioblastoma remains universally lethal, with rapid recurrence and a median survival of less than two years. Current CAR T approaches in glioblastoma have been limited by a lack of uniformly expressed and therapeutically actionable antigens. Using integrated single-cell and single-nucleus atlases, we identify PTPRZ1 as a consistently and highly expressed surface antigen across malignant glioblastoma states with minimal expression in non-neoplastic neural lineages. To translate this target, we developed a binder engineering pipeline combining mouse immunization, phage display with counter-selection against PTPRG, and yeast based directed evolution to generate a panel of scFv and nanobody binders with a spectrum of affinities that recognize the same PTPRZ1 epitope. This panel enables systematic tuning of CAR antigen sensitivity and functional thresholds and allows direct comparison of how binder format and affinity shape CAR activity against endogenous antigen. We incorporated these affinity-graded binders into a modular CAR backbone and constructed a combinatorial CAR library that varies hinge domains, transmembrane regions, and costimulatory modules. Primary human T cells transduced with pooled CAR libraries were screened against patient-derived glioma stem cells to quantify how each architectural module influences CAR function as an isolated component and how combinations of modules synergize to enhance activation, cytotoxicity, proliferation, resistance to exhaustion, and durability under chronic stimulation. This screening strategy also enabled the identification of recurrent architectural features that support persistence and metabolic fitness in solid tumor settings. Individual validation studies confirmed that both scFv and nanobody CARs targeting the identical epitope exhibit distinct activation and persistence profiles, and that optimal performance arises from specific pairings of hinge, transmembrane, and costimulatory domains. Safety studies using human epilepsy-derived cortical slice cultures reveal minimal off-tumor cytotoxicity and preserved neural architecture following exposure to PTPRZ1-targeting CAR T cells. Collectively, these data nominate affinity-tuned PTPRZ1 binders and optimized CAR architectures as strong candidates for translation and provide generalizable design principles for improving CAR T therapy in solid tumors.
利益披露 Disclosure
A. A. Mohan, None.. A. Gonzalez, None.. J. Sampson, None.

← 返回 AACR 2026 检索